Remdesivir May Help Avoid Hospitalization for Outpatients with COVID-19 at Risk for Progression

What**'**s the**news. * A three-day course of remdesivir resulted in an 87% lower risk of hospitalization or death by day 28 than a placebo for nonhospitalized patients with COVID-19 who were at high risk for progression to more severe COVID-19, says a [December 22, 2021, study in The New England Journal of Medicine*](https://www.nejm.org/doi/10.1056/NEJMoa2116846).